glp 1 agonists for alcohol use disorder Weight Loss Drugs May Also Curb Substance Disorders GLP-1 Agonists for Alcohol Use
Description
Responses to the less chartered topics will provide an insight into better and safer clinical practices
NCLs consumer alert reflects a different market for compounded GLP-1 weight-loss drugs than what existed a year ago
In addition to stimulating insulin secretion, these drugs can reduce glucagon production and peak postprandial glucose levels
For people with type 2 diabetes and obesity, guidelines increasingly favor choosing GLP-1-based agents early in the treatment regimen, particularly when weight and cardiorenal risk are central goals
